Development of a Universal In Vivo Predictive Dissolution Method for a Borderline BCS III/IV Drug Guided by Modeling and Simulations─Acyclovir as a Case Study Article Swipe
Mauricio A. García
,
Fernando Tapia
,
Benjamín Escares
,
Peter Langguth
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1021/acs.molpharmaceut.5c00981
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1021/acs.molpharmaceut.5c00981
Establishing in vivo predictive dissolution (IPD) conditions requires the consideration of biopredictive aspects during dissolution. For acyclovir, lower dose strengths (200 and 400 mg) can dissolve completely in the gastrointestinal fluids. However, luminal concentrations after administering the highest strength (800 mg) exceed the BCS solubility threshold. Given its poor permeability, sink conditions are not granted for the highest strength. In this study, a universal IPD method for acyclovir tablets was developed using the mini-vessel/mini-paddle apparatus. Computational simulations in a physiologically based pharmacokinetic (PBPK) model further guided the development. Apparatuses with different volumes and stirring conditions were explored, and results served as input for the model. Dissolution of 800 mg of acyclovir tablets in 900 mL of medium largely overpredicted observed plasma profiles due to poor resemblance of nonsink conditions in the lumen. Conversely, dissolution in the mini-vessel filled with 135 mL of HCl, pH 2.0, at 150 rpm, produced accurate predictions of plasma profiles, without affecting previous successful predictions with the lowest strength tablets. Furthermore, in-human and virtual bioequivalence studies confirmed the predictive potential of this method. Therefore, the aforementioned dissolution conditions can be considered as a universal IPD method for acyclovir immediate-release tablets.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1021/acs.molpharmaceut.5c00981
- OA Status
- hybrid
- References
- 31
- OpenAlex ID
- https://openalex.org/W4414413868
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414413868Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1021/acs.molpharmaceut.5c00981Digital Object Identifier
- Title
-
Development of a Universal In Vivo Predictive Dissolution Method for a Borderline BCS III/IV Drug Guided by Modeling and Simulations─Acyclovir as a Case StudyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-22Full publication date if available
- Authors
-
Mauricio A. García, Fernando Tapia, Benjamín Escares, Peter LangguthList of authors in order
- Landing page
-
https://doi.org/10.1021/acs.molpharmaceut.5c00981Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1021/acs.molpharmaceut.5c00981Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
31Number of works referenced by this work
Full payload
| id | https://openalex.org/W4414413868 |
|---|---|
| doi | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| ids.doi | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40984010 |
| ids.openalex | https://openalex.org/W4414413868 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | Q000737 |
| mesh[0].descriptor_ui | D000212 |
| mesh[0].is_major_topic | True |
| mesh[0].qualifier_name | chemistry |
| mesh[0].descriptor_name | Acyclovir |
| mesh[1].qualifier_ui | Q000493 |
| mesh[1].descriptor_ui | D000212 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | pharmacokinetics |
| mesh[1].descriptor_name | Acyclovir |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D006801 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Humans |
| mesh[3].qualifier_ui | Q000737 |
| mesh[3].descriptor_ui | D013607 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | chemistry |
| mesh[3].descriptor_name | Tablets |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D012995 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Solubility |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D003198 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Computer Simulation |
| mesh[6].qualifier_ui | Q000493 |
| mesh[6].descriptor_ui | D000998 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | pharmacokinetics |
| mesh[6].descriptor_name | Antiviral Agents |
| mesh[7].qualifier_ui | Q000737 |
| mesh[7].descriptor_ui | D000998 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | chemistry |
| mesh[7].descriptor_name | Antiviral Agents |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D008954 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Models, Biological |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D013810 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Therapeutic Equivalency |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D065546 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Drug Liberation |
| mesh[11].qualifier_ui | Q000737 |
| mesh[11].descriptor_ui | D000212 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | chemistry |
| mesh[11].descriptor_name | Acyclovir |
| mesh[12].qualifier_ui | Q000493 |
| mesh[12].descriptor_ui | D000212 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | pharmacokinetics |
| mesh[12].descriptor_name | Acyclovir |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | Q000737 |
| mesh[14].descriptor_ui | D013607 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | chemistry |
| mesh[14].descriptor_name | Tablets |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D012995 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Solubility |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D003198 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Computer Simulation |
| mesh[17].qualifier_ui | Q000493 |
| mesh[17].descriptor_ui | D000998 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pharmacokinetics |
| mesh[17].descriptor_name | Antiviral Agents |
| mesh[18].qualifier_ui | Q000737 |
| mesh[18].descriptor_ui | D000998 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | chemistry |
| mesh[18].descriptor_name | Antiviral Agents |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D008954 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Models, Biological |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D013810 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Therapeutic Equivalency |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D065546 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Drug Liberation |
| type | article |
| title | Development of a Universal In Vivo Predictive Dissolution Method for a Borderline BCS III/IV Drug Guided by Modeling and Simulations─Acyclovir as a Case Study |
| biblio.issue | 10 |
| biblio.volume | 22 |
| biblio.last_page | 6246 |
| biblio.first_page | 6237 |
| topics[0].id | https://openalex.org/T10256 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9994999766349792 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3003 |
| topics[0].subfield.display_name | Pharmaceutical Science |
| topics[0].display_name | Drug Solubulity and Delivery Systems |
| topics[1].id | https://openalex.org/T11124 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9980000257492065 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Protein purification and stability |
| topics[2].id | https://openalex.org/T10920 |
| topics[2].field.id | https://openalex.org/fields/30 |
| topics[2].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[2].score | 0.9970999956130981 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/3003 |
| topics[2].subfield.display_name | Pharmaceutical Science |
| topics[2].display_name | Advanced Drug Delivery Systems |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| language | en |
| locations[0].id | doi:10.1021/acs.molpharmaceut.5c00981 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S204562082 |
| locations[0].source.issn | 1543-8384, 1543-8392 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1543-8384 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Molecular Pharmaceutics |
| locations[0].source.host_organization | https://openalex.org/P4310320006 |
| locations[0].source.host_organization_name | American Chemical Society |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320006 |
| locations[0].source.host_organization_lineage_names | American Chemical Society |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Molecular Pharmaceutics |
| locations[0].landing_page_url | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| locations[1].id | pmid:40984010 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Molecular pharmaceutics |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40984010 |
| locations[2].id | pmh:oai:europepmc.org:11313243 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12505258 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5020288081 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5618-3318 |
| authorships[0].author.display_name | Mauricio A. García |
| authorships[0].countries | CL |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I162148367 |
| authorships[0].affiliations[0].raw_affiliation_string | Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile |
| authorships[0].institutions[0].id | https://openalex.org/I162148367 |
| authorships[0].institutions[0].ror | https://ror.org/04teye511 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I162148367 |
| authorships[0].institutions[0].country_code | CL |
| authorships[0].institutions[0].display_name | Pontificia Universidad Católica de Chile |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mauricio A. García |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile |
| authorships[1].author.id | https://openalex.org/A5085203471 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Fernando Tapia |
| authorships[1].countries | CL |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I162148367 |
| authorships[1].affiliations[0].raw_affiliation_string | Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile |
| authorships[1].institutions[0].id | https://openalex.org/I162148367 |
| authorships[1].institutions[0].ror | https://ror.org/04teye511 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I162148367 |
| authorships[1].institutions[0].country_code | CL |
| authorships[1].institutions[0].display_name | Pontificia Universidad Católica de Chile |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Fernando Tapia |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile |
| authorships[2].author.id | https://openalex.org/A5119698194 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Benjamín Escares |
| authorships[2].countries | CL |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I69737025 |
| authorships[2].affiliations[0].raw_affiliation_string | Universidad de Chile |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I162148367 |
| authorships[2].affiliations[1].raw_affiliation_string | Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile |
| authorships[2].affiliations[2].raw_affiliation_string | Departamento de Ciencias y Tecnología Farmacéuticas |
| authorships[2].institutions[0].id | https://openalex.org/I162148367 |
| authorships[2].institutions[0].ror | https://ror.org/04teye511 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I162148367 |
| authorships[2].institutions[0].country_code | CL |
| authorships[2].institutions[0].display_name | Pontificia Universidad Católica de Chile |
| authorships[2].institutions[1].id | https://openalex.org/I69737025 |
| authorships[2].institutions[1].ror | https://ror.org/047gc3g35 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I69737025 |
| authorships[2].institutions[1].country_code | CL |
| authorships[2].institutions[1].display_name | University of Chile |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Benjamín Escares |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Departamento de Ciencias y Tecnología Farmacéuticas, Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Campus San Joaquín, Macul, Santiago 7820436, Chile, Universidad de Chile |
| authorships[3].author.id | https://openalex.org/A5007186343 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3758-7581 |
| authorships[3].author.display_name | Peter Langguth |
| authorships[3].countries | DE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I197323543 |
| authorships[3].affiliations[0].raw_affiliation_string | Johannes Gutenberg University Mainz |
| authorships[3].institutions[0].id | https://openalex.org/I197323543 |
| authorships[3].institutions[0].ror | https://ror.org/023b0x485 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I197323543 |
| authorships[3].institutions[0].country_code | DE |
| authorships[3].institutions[0].display_name | Johannes Gutenberg University Mainz |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Peter Langguth |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Johannes Gutenberg University Mainz |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Development of a Universal In Vivo Predictive Dissolution Method for a Borderline BCS III/IV Drug Guided by Modeling and Simulations─Acyclovir as a Case Study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10256 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9994999766349792 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3003 |
| primary_topic.subfield.display_name | Pharmaceutical Science |
| primary_topic.display_name | Drug Solubulity and Delivery Systems |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1021/acs.molpharmaceut.5c00981 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S204562082 |
| best_oa_location.source.issn | 1543-8384, 1543-8392 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1543-8384 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Molecular Pharmaceutics |
| best_oa_location.source.host_organization | https://openalex.org/P4310320006 |
| best_oa_location.source.host_organization_name | American Chemical Society |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320006 |
| best_oa_location.source.host_organization_lineage_names | American Chemical Society |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Molecular Pharmaceutics |
| best_oa_location.landing_page_url | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| primary_location.id | doi:10.1021/acs.molpharmaceut.5c00981 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S204562082 |
| primary_location.source.issn | 1543-8384, 1543-8392 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1543-8384 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Molecular Pharmaceutics |
| primary_location.source.host_organization | https://openalex.org/P4310320006 |
| primary_location.source.host_organization_name | American Chemical Society |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320006 |
| primary_location.source.host_organization_lineage_names | American Chemical Society |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Molecular Pharmaceutics |
| primary_location.landing_page_url | https://doi.org/10.1021/acs.molpharmaceut.5c00981 |
| publication_date | 2025-09-22 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4394724889, https://openalex.org/W4405438701, https://openalex.org/W4400213051, https://openalex.org/W4402976668, https://openalex.org/W4403756316, https://openalex.org/W2588931050, https://openalex.org/W3008339697, https://openalex.org/W2068571157, https://openalex.org/W168756651, https://openalex.org/W1498305210, https://openalex.org/W1970728958, https://openalex.org/W3207552835, https://openalex.org/W2313724273, https://openalex.org/W2792636470, https://openalex.org/W3208495876, https://openalex.org/W2321426002, https://openalex.org/W1982785607, https://openalex.org/W2436228657, https://openalex.org/W2784110689, https://openalex.org/W2032571619, https://openalex.org/W4319864134, https://openalex.org/W1848223682, https://openalex.org/W2319905427, https://openalex.org/W2799745100, https://openalex.org/W3129615893, https://openalex.org/W3040552380, https://openalex.org/W4405486889, https://openalex.org/W3047776908, https://openalex.org/W4403229238, https://openalex.org/W3153138398, https://openalex.org/W3087144030 |
| referenced_works_count | 31 |
| abstract_inverted_index.a | 62, 78, 186 |
| abstract_inverted_index.In | 59 |
| abstract_inverted_index.as | 100, 185 |
| abstract_inverted_index.at | 145 |
| abstract_inverted_index.be | 183 |
| abstract_inverted_index.in | 1, 27, 77, 112, 129, 134 |
| abstract_inverted_index.mL | 114, 140 |
| abstract_inverted_index.mg | 108 |
| abstract_inverted_index.of | 10, 106, 109, 115, 126, 141, 151, 174 |
| abstract_inverted_index.pH | 143 |
| abstract_inverted_index.to | 123 |
| abstract_inverted_index.135 | 139 |
| abstract_inverted_index.150 | 146 |
| abstract_inverted_index.400 | 22 |
| abstract_inverted_index.800 | 107 |
| abstract_inverted_index.900 | 113 |
| abstract_inverted_index.BCS | 43 |
| abstract_inverted_index.For | 15 |
| abstract_inverted_index.IPD | 64, 188 |
| abstract_inverted_index.and | 21, 92, 97, 166 |
| abstract_inverted_index.are | 52 |
| abstract_inverted_index.can | 24, 182 |
| abstract_inverted_index.due | 122 |
| abstract_inverted_index.for | 55, 66, 102, 190 |
| abstract_inverted_index.its | 47 |
| abstract_inverted_index.mg) | 23, 40 |
| abstract_inverted_index.not | 53 |
| abstract_inverted_index.the | 8, 28, 36, 42, 56, 72, 86, 103, 130, 135, 160, 171, 178 |
| abstract_inverted_index.was | 69 |
| abstract_inverted_index.(200 | 20 |
| abstract_inverted_index.(800 | 39 |
| abstract_inverted_index.2.0, | 144 |
| abstract_inverted_index.HCl, | 142 |
| abstract_inverted_index.dose | 18 |
| abstract_inverted_index.poor | 48, 124 |
| abstract_inverted_index.rpm, | 147 |
| abstract_inverted_index.sink | 50 |
| abstract_inverted_index.this | 60, 175 |
| abstract_inverted_index.vivo | 2 |
| abstract_inverted_index.were | 95 |
| abstract_inverted_index.with | 89, 138, 159 |
| abstract_inverted_index.(IPD) | 5 |
| abstract_inverted_index.Given | 46 |
| abstract_inverted_index.after | 34 |
| abstract_inverted_index.based | 80 |
| abstract_inverted_index.input | 101 |
| abstract_inverted_index.lower | 17 |
| abstract_inverted_index.model | 83 |
| abstract_inverted_index.using | 71 |
| abstract_inverted_index.(PBPK) | 82 |
| abstract_inverted_index.during | 13 |
| abstract_inverted_index.exceed | 41 |
| abstract_inverted_index.filled | 137 |
| abstract_inverted_index.guided | 85 |
| abstract_inverted_index.lowest | 161 |
| abstract_inverted_index.lumen. | 131 |
| abstract_inverted_index.medium | 116 |
| abstract_inverted_index.method | 65, 189 |
| abstract_inverted_index.model. | 104 |
| abstract_inverted_index.plasma | 120, 152 |
| abstract_inverted_index.served | 99 |
| abstract_inverted_index.study, | 61 |
| abstract_inverted_index.aspects | 12 |
| abstract_inverted_index.fluids. | 30 |
| abstract_inverted_index.further | 84 |
| abstract_inverted_index.granted | 54 |
| abstract_inverted_index.highest | 37, 57 |
| abstract_inverted_index.largely | 117 |
| abstract_inverted_index.luminal | 32 |
| abstract_inverted_index.method. | 176 |
| abstract_inverted_index.nonsink | 127 |
| abstract_inverted_index.results | 98 |
| abstract_inverted_index.studies | 169 |
| abstract_inverted_index.tablets | 68, 111 |
| abstract_inverted_index.virtual | 167 |
| abstract_inverted_index.volumes | 91 |
| abstract_inverted_index.without | 154 |
| abstract_inverted_index.However, | 31 |
| abstract_inverted_index.accurate | 149 |
| abstract_inverted_index.dissolve | 25 |
| abstract_inverted_index.in-human | 165 |
| abstract_inverted_index.observed | 119 |
| abstract_inverted_index.previous | 156 |
| abstract_inverted_index.produced | 148 |
| abstract_inverted_index.profiles | 121 |
| abstract_inverted_index.requires | 7 |
| abstract_inverted_index.stirring | 93 |
| abstract_inverted_index.strength | 38, 162 |
| abstract_inverted_index.tablets. | 163, 193 |
| abstract_inverted_index.acyclovir | 67, 110, 191 |
| abstract_inverted_index.affecting | 155 |
| abstract_inverted_index.confirmed | 170 |
| abstract_inverted_index.developed | 70 |
| abstract_inverted_index.different | 90 |
| abstract_inverted_index.explored, | 96 |
| abstract_inverted_index.potential | 173 |
| abstract_inverted_index.profiles, | 153 |
| abstract_inverted_index.strength. | 58 |
| abstract_inverted_index.strengths | 19 |
| abstract_inverted_index.universal | 63, 187 |
| abstract_inverted_index.Therefore, | 177 |
| abstract_inverted_index.acyclovir, | 16 |
| abstract_inverted_index.apparatus. | 74 |
| abstract_inverted_index.completely | 26 |
| abstract_inverted_index.conditions | 6, 51, 94, 128, 181 |
| abstract_inverted_index.considered | 184 |
| abstract_inverted_index.predictive | 3, 172 |
| abstract_inverted_index.solubility | 44 |
| abstract_inverted_index.successful | 157 |
| abstract_inverted_index.threshold. | 45 |
| abstract_inverted_index.Apparatuses | 88 |
| abstract_inverted_index.Conversely, | 132 |
| abstract_inverted_index.Dissolution | 105 |
| abstract_inverted_index.dissolution | 4, 133, 180 |
| abstract_inverted_index.mini-vessel | 136 |
| abstract_inverted_index.predictions | 150, 158 |
| abstract_inverted_index.resemblance | 125 |
| abstract_inverted_index.simulations | 76 |
| abstract_inverted_index.Establishing | 0 |
| abstract_inverted_index.Furthermore, | 164 |
| abstract_inverted_index.development. | 87 |
| abstract_inverted_index.dissolution. | 14 |
| abstract_inverted_index.Computational | 75 |
| abstract_inverted_index.administering | 35 |
| abstract_inverted_index.biopredictive | 11 |
| abstract_inverted_index.consideration | 9 |
| abstract_inverted_index.overpredicted | 118 |
| abstract_inverted_index.permeability, | 49 |
| abstract_inverted_index.aforementioned | 179 |
| abstract_inverted_index.bioequivalence | 168 |
| abstract_inverted_index.concentrations | 33 |
| abstract_inverted_index.pharmacokinetic | 81 |
| abstract_inverted_index.physiologically | 79 |
| abstract_inverted_index.gastrointestinal | 29 |
| abstract_inverted_index.immediate-release | 192 |
| abstract_inverted_index.mini-vessel/mini-paddle | 73 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5020288081 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 4 |
| corresponding_institution_ids | https://openalex.org/I162148367 |
| citation_normalized_percentile.value | 0.37494481 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |